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Genome organization and reverse genetic analysis of a type I
feline coronavirus
Abstract
In this study we report the complete sequence and genome organization of the serotype I feline
coronavirus (FCoV) strain Black. Furthermore, a reverse genetic system was established for this FCoV
strain by cloning a full-length cDNA copy into vaccinia virus. This clone served as basis for the
generation of recombinant FCoV (recFCoV) that was shown to bear the same features in vitro as the
parental FCoV. Using this system, accessory 3abc genes in the FCoV genome were replaced by green
fluorescent protein (recFCoV-GFP) and Renilla luciferase genes (recFCoV-RL). In addition, we showed
that feline CD14(+) blood monocytes and dendritic cells can be easily detected after infection with
recFCoV-GFP. Thus, our established reverse genetic system provides a suitable tool to study the
molecular biology of serotype I FCoV.
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In this study we report the complete sequence and genome organization of the serotype I feline coronavirus
(FCoV) strain Black. Furthermore, a reverse genetic system was established for this FCoV strain by cloning a
full-length cDNA copy into vaccinia virus. This clone served as basis for the generation of recombinant FCoV
(recFCoV) that was shown to bear the same features in vitro as the parental FCoV. Using this system, accessory
3abc genes in the FCoV genome were replaced by green fluorescent protein (recFCoV-GFP) and Renilla
luciferase genes (recFCoV-RL). In addition, we showed that feline CD14 blood monocytes and dendritic cells
can be easily detected after infection with recFCoV-GFP. Thus, our established reverse genetic system provides
a suitable tool to study the molecular biology of serotype I FCoV.
Coronaviruses (CoVs) are enveloped, positive-strand RNA
viruses that mainly cause enteric and respiratory diseases in
humans and animals. Together with arteriviruses, toroviruses,
and roniviruses, they belong to the order Nidovirales. CoVs are
classified into three groups. This classification was initially
based on serological investigations and has received support from
recent phylogenetic analyses (19). Feline CoVs (FCoVs) are
members of group I and are placed together with the closely
related porcine transmissible gastroenteritis virus and canine CoV
(CCoV) into the CoV subgroup Ia (18). Members of the more
distantly related subgroup Ib CoVs are human CoVs (HCoVs)
229E and NL63 and porcine epidemic diarrhea virus.
FCoVs cause infections in wild and domestic Felidae and are
widespread, with seropositivity of 20 to 60% in domestic cats and
up to 90% in animal shelters or households with multiple cats
(25). Infected animals often develop persistent infection and shed
the virus over longer periods of time (1, 2, 17, 24, 26). On the basis
of serological differences, FCoVs can be separated into type I and
type II (29, 30, 43). Eighty to 90% of the naturally occurring
infections are caused by type I (2, 31, 34, 38). Type II FCoVs most
likely have arisen by homologous recombination between type I
FCoV and CCoV (27, 55). As a result of this recombination, the
spike (S) gene and adjacent regions of type I FCoV were replaced
by the corresponding part of the CCoV genome. The presence of
different S genes is reflected by different growth characteristics in
vitro. For type II FCoV, the feline aminopeptidase N (fAPN) has
been identified as a cellular receptor (53). While type II FCoV
can be easily propagated in cell culture, type I FCoV isolates
usually grow only poorly in cell culture. Consequently, most in-
vestigations in the last years concentrated on type II FCoV (12,
14, 21, 44), although their prevalence is much lower than that of
type I.
Interestingly, both serotypes exist as two biotypes; the rather
benign feline enteric CoV (FECV) causes subclinical, often
persistent infections, whereas feline infectious peritonitis virus
(FIPV) is highly virulent and causes FIP, a fatal, systemic
granulomatous disease. In the development of the disease
FIPV-infected monocytes are thought to play an important
role in the dissemination of the virus throughout the body (20,
36, 39). It has been suggested that virulent FIPV arises by
mutation from parental FECV in the individual, persistently
infected host (54). However, despite the high prevalence of
FCoV infection in the cat population, FIP develops in only
about 5% of these animals. It is not yet clear which alterations
in the FCoV genome are responsible for the generation of
FIPV from FECV, but mutations in accessory genes and the S
gene have been proposed to be associated with the generation
of FIP (33, 54).
Although a reverse genetic system based on targeted recom-
bination has already been established for type II FIPV 79-1146
(21), the differences between FECV and FIPV have not yet
been delineated on the genetic level. It could be shown that the
accessory genes are not required for in vitro replication, but
they are important for the virulence in vivo (21, 22). Never-
theless, a major obstacle of these studies is the fact that mu-
tagenesis by targeted recombination is, for technical reasons,
restricted to the 3 third of the genome. Therefore, the 5
untranslated region (UTR) and the entire replicase gene are
not amenable to mutagenesis. There is actually accumulating
evidence that some CoV replicase gene products are involved
in virus-host interactions and represent important pathogenic-
ity factors (48, 60). Thus, it is desirable to extend FCoV reverse
genetics to the genetic manipulation of the entire FCoV ge-
nome and to the much more widely distributed type I FCoV
serotype.
In this study we report the complete sequence and genome
organization of the type I FCoV strain Black (4). We have
developed a versatile reverse genetic system for this virus using
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a vaccinia virus cloning vector. This system allows the genetic
manipulation of the entire genome including the 5 UTR and
the replicase gene. The rescued recombinant FCoV Black
(recFCoV) exhibits growth characteristics in vitro similar to
the parental FCoV strain Black. Replacement of accessory
3abc protein genes by green fluorescent protein (GFP) and
Renilla luciferase (RL) genes allowed us to demonstrate that
replication of type I FCoV in monocytes, macrophages, and
dendritic cells (DCs) is limited.
MATERIALS AND METHODS
Viruses and cells. Felis catus whole fetus 4 cells (FCWF-4) and baby hamster
kidney cells (BHK-21) were originally purchased from the American Type Cul-
ture Collection and obtained from the diagnostic laboratory of our institute.
Monkey kidney (CV-1) cells were purchased from the European Collection of
Cell Cultures. D980R cells were a kind gift from G. L. Smith, Imperial College,
London, United Kingdom. BHK-Tet/ON cells were a kind gift from N. Tautz,
Justus Liebig Universita¨t, Giessen, Germany. All cells were maintained in min-
imal essential medium supplemented with 10% fetal bovine serum, penicillin
(100 U/ml) and streptomycin (100 U/ml). The fowlpox virus was a kind gift from
P. Britton, Institute for Animal Health, Compton, United Kingdom. The FCoV
Black strain was a kind gift from R.J. de Groot (Utrecht University, The Neth-
erlands). FCoV Black and recombinant FCoV were propagated in FCWF cells.
The vNotI/tk vaccinia virus, recombinant vaccinia viruses, and fowlpox virus were
propagated, titrated, and purified as described previously (52).
Plasmid construction and generation of recombinant vaccinia viruses. The
complete sequence of type I FCoV strain Black was determined by sequencing
overlapping cDNA fragments generated from viral RNA. On the basis of the
consensus sequence, a set of seven plasmid clones (A, BC-1, 2, 3, D, E, and F)
spanning the entire FCoV Black genome were generated. Plasmid pA is based on
pGem T-easy (Promega) and contains sequences corresponding to nucleotides
(nt) 1 to 5083 of the FCoV Black genome, preceded by a G nucleotide, a T7
promoter, and a Bsp120I cleavage site and followed by a BsaI cleavage site with
reverse orientation. Plasmids pBC-1, pBC-2, pBC-3, and pD are based on pGem
T-easy and contain sequences corresponding to nt 4389 to 8769, 8161 to 12680,
12031 to 16404, and 15775 to 20672 of the FCoV Black genome, respectively.
Plasmid pE is based on pGem T-easy and contains sequences corresponding to
nt 20568 to 24873 of the FCoV Black genome followed by a BsmBI cleavage site
with reverse orientation. Plasmid pF contains a BsmBI cleavage site upstream of
the cloned FCoV Black sequence corresponding to nt 24844 to 29228 followed by
a synthetic poly(A) tail, a ClaI cleavage site, a hepatitis delta ribozyme sequence,
and a Bsp120I restriction site.
Introduction of the full-length FCoV cDNA in the vaccinia virus genome was
carried out in two steps. First, fragments A, D, E, and F were ligated. DNA
fragment A is derived from plasmid pA after Bsp120I and BsaI digestion, treat-
ment with alkaline phosphatase, and gel purification. DNA fragment D resulted
from digestion of the plasmid pD with BsmBI and gel purification. DNA frag-
ment E resulted from cleavage of the plasmid pE with BsmBI and gel purifica-
tion. DNA fragment F was generated from the plasmid pF after BsmBI and
Bsp120I digestion, treatment with alkaline phosphatase, and gel purification.
About 100 to 500 ng of each DNA fragment (A, D, E, and F) was in vitro ligated
using T4 DNA ligase, and the resulting product was ligated without further
purification to the NotI-cleaved vNotI/tk vaccinia virus DNA in the presence of
NotI enzyme. The resulting products from this ligation were used directly for
transfection of fowlpox virus-infected CV-1 cells. The recombinant vaccinia
viruses (vrecFCoV-ADEF) were isolated as described previously (52). Second,
the missing part of the FCoV Black genome (nt 5083 to 15775) was introduced
by two rounds of vaccinia virus-mediated homologous recombination using
guanosine-phosphoribosyl-transferase (GPT) as a positive and negative selection
marker, as described previously (8, 28). For this purpose DNA fragments BC-1
and BC-3, corresponding to FCoV Black nt 4389 to 8769 and 12031 to 16404,
respectively, were cloned upstream and downstream of the gpt gene in the plasmid
pGPT-1 (28). The resulting plasmid (pGPT-BC-1/3) contains fragment BC-1 up-
stream and fragment BC-3 downstream of the gpt gene and was used for vaccinia
virus-mediated homologous recombination. The resulting gpt gene-containing re-
combinant virus vrecFCoV-BC was selected using GPT as a positive selection
marker. To obtain vrecFCoV containing the complete FCoV Black cDNA,
vrecFCoV-BC-2 was used for vaccinia virus-mediated homologous recombination
with plasmid pBC-2 containing FCoV Black nt 8161 to 12680. The resulting recom-
binant virus vrecFCoV was selected using GPT as a negative selection marker.
The recombinant vaccinia virus vrecFcoV was used to replace the accessory
3abc genes by the GFP or RL gene by two rounds of vaccinia virus-mediated
homologous recombination. First, plasmid pGPT3abc was constructed to en-
code FCoV Black nt 24224 to 24812 and 25768 to 26378 upstream and down-
stream of the gpt gene. Recombination of vrecFCoV with plasmid pGPT3abc
resulted in the isolation of the recombinant vaccinia virus vrecFCoV-GPT3abc.
To construct the recombinant GFP-encoding vaccinia virus vrecFCoV-GFP,
vaccinia virus vrecFCoV-GPT3abc was used for recombination with the plas-
mid pFCoV-GFP, encoding FCoV Black nt 24224 to 24812 upstream and FCoV
Black nt 25768 to 26378 downstream of the GFP sequence. The resulting re-
combinant vaccinia virus vrecFCoV-GFP was obtained after gpt negative selec-
tion. To construct the recombinant RL-encoding vaccinia virus vrecFCoV-RL,
vaccinia virus vrecFCoV-GPT3abc was used for recombination with the plas-
mid pFCoV-RL, encoding FCoV Black nt 24224 to 24812 upstream and FCoV
Black nt 25768 to 26378 downstream of the RL sequence. The resulting recom-
binant vaccinia virus, vrecFCoV-RL, was obtained after gpt negative selection.
Sequence analysis and Northern blotting. The sequences of all generated
plasmids and insert DNAs of recombinant vaccinia viruses were verified by
sequence analysis.
Northern blot analysis was done using poly(A)-containing RNA isolated from
FCoV Black-infected (multiplicity of infection [MOI] of 0.1) FCWF cells and
electrophoresis on formaldehyde 1% agarose gel. After a blotting step, a 32P-
labeled probe directed against the 7ab genes of the FCoV Black genome was
used to detect genomic RNA and subgenomic RNAs (52).
To determine the leader-body junctions of FCoV-Black subgenomic mRNAs,
poly(A)-containing RNA from FCoV Black-infected FCWF cells was reverse
transcribed using Superscript II reverse transcriptase (Invitrogen) with primers
specific for the unique region of a subgenomic mRNA, followed by a PCR using
a leader- and a body-specific primer pair. The PCR products were subjected to
standard sequence analysis using an ABI 310 Prism Genetic Analyzer.
Generation of a BHK-21-derived cell line that stably expresses the FCoV
strain Black N protein. The cell line BHK-FCoV-N expressing the FCoV Black
nucleocapsid (N) protein is based on BHK-Tet/ON cells that were a kind gift
from N. Tautz, Justus Liebig Universita¨t, Giessen, Germany. A plasmid encoding
the FCoV Black N protein was transfected into BHK-Tet/ON cells, and single
colonies were collected after hygromycin selection (300 g/ml). Expression of
FCoV strain Black N protein was assessed by Western blot analysis 16 h after the
addition of doxycycline (2 mg/ml) to the culture medium.
Recovery of the recombinant FCoV. DNA from vaccinia virus vrecFCoV-,
vrecFCoV-GFP-, or vrecFCoV-RL-infected BHK-21 cells was prepared as de-
scribed previously (52). After ClaI digestion, phenol extraction, and ethanol
precipitation, the DNA was used as a template for in vitro transcription, as
described previously (52). A total of 10 g of the resulting RNA was electropo-
rated into BHK cells that express the FCoV strain Black N protein (BHK-FCoV-
N). The electroporated cells were cocultivated with FCWF cells, and after a 48-h
incubation the supernatant was harvested and added to fresh FCWF cells. At 24
to 48 h postinfection cytopathic effect was observed, and the cell supernatant
containing recombinant FCoV was collected and used for further characteriza-
tion. Virus supernatant obtained after recFCoV rescue was used without plaque
purification.
Measurement of RL expression. recFCoV-RL-infected FCWF cells (MOI of
0.1) were harvested at different time points using lysis buffer from an RL assay
system kit (Promega). Intracellular RL expression was measured according to
the manufacturer’s instructions.
Isolation of blood monocytes and differentiation to DCs. Peripheral blood
mononuclear cells were purified by Ficoll-Paque separation from 15 ml of hep-
arinized blood obtained from specific-pathogen-free cats. Anti-human CD14
magnetic beads (Miltenyi Biotec) were used to obtain CD14 feline monocytes.
To obtain differentiated feline macrophages and DCs, CD14 feline monocytes
were cultured for 7 days using either human recombinant granulocyte macro-
phage colony-stimulating factor (hrGM-CSF) or hrGM-CSF together with hu-
man recombinant interleukin-4 (IL-4), respectively, as described previously (49).
Nucleotide sequence accession number. The complete genomic sequence of
FCoV strain Black was deposited in GenBank database under accession number
EU186072.
RESULTS
Genome organization of type I FCoV strain Black. The virus
used in our experiments was originally isolated in the 1970s
from an FIPV-infected cat and was then named Tennessee
strain (TN-406). It was maintained by animal passage and
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stored as a liver homogenate. John Black was able to success-
fully propagate the virus in feline cell culture, and this virus
was later named the Black strain (4). The complete genomic
sequence of type I FCoV strain Black was determined by
sequencing overlapping cDNA fragments generated by reverse
transcription-PCR (RT-PCR) from viral RNA. The FCoV
strain Black genome has a size of 29,228 nt, excluding the 3
poly(A) tail, and shows typical genome organization for CoVs
(Fig. 1a). The 5 UTR consists of 311 nt including the leader
sequence (nt 1 to 92) and the transcription-regulatory se-
quence (TRS) with the core TRS 5-CUAAAC-3 (nt 93 to 98)
which controls mRNA synthesis. Like type II FCoV 79-1146,
the 5 UTR of strain Black harbors a short open reading frame
(ORF; nt 116 to 127) potentially encoding the tripeptide Met-
Lys-Pro. The 3UTR comprises 275 nt followed by the poly(A)
tail. Approximately two-thirds of the genome is covered by the
replicase gene comprising ORFs 1a (nt 312 to 12407) and 1b
(nt 12362 to 20407). Translation of the CoV replicase gene
FIG. 1. FCoV type I genome organization. (a) The type I FCoV genome, ORFs, and TRS elements are shown together with the characteristic
nested set of viral sgmRNAs. Boxes of viral mRNAs indicate the predicted translationally active “unique” region of each particular mRNA. L,
FCoV leader sequence; (A)n, poly(A) tail. (b) Northern blot analysis from poly(A)-containing RNA isolated from type I FCoV strain Black-
infected FCWF cells. A 32P-labeled probe directed against the 7ab genes of the type I FCoV genome was used to detect genomic RNA and
sgRNAs. (c) Alignment of type I FCoV strain Black TRS elements that direct the synthesis of sgmRNAs. Nucleotides matching the leader TRS
are underlined. The conserved TRS core is shaded in gray.
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gives rise to the primary translation products polyprotein 1a
(pp1a) and pp1ab, which are processed by virus-encoded pro-
teinases. Based on sequence comparison with other group I
CoV replicase genes, we have identified three putative pa-
pain-like proteinase cleavage sites and 11 putative main
proteinase cleavage sites. Thus, we predict that proteolytic
processing of the FCoV strain Black pp1a/1ab gives rise to
16 processed end products, nonstructural protein 1 (nsp-1)
to nsp-16 (Table 1). Downstream of the replicase gene we
identified the canonical four structural genes encoding the
proteins S (nt 20404 to 24798), envelope (E) (nt 25826 to
26074), membrane (M) (nt 26085 to 26876), and N (nt 26889 to
28022). FCoV strain Black contains sequences corresponding
to the known five additional ORFs coding for the accessory
proteins 3abc (nt 24810 to 25839) and 7ab (nt 28027 to 28954).
There is a large deletion of 62 nt at the border of the accessory
3b and 3c genes, leading to translational readthrough of ORFs
3b and 3c, as described previously for FIPV Black (54). The 7b
gene contains a nonsense mutation at nt 28442 (C to T) re-
sulting in early termination of the 7b protein compared to
other FCoV isolates (data not shown). CoV structural and
accessory proteins downstream of the replicase gene are trans-
lated from a set of subgenomic RNAs (sgRNAs) that contain
the leader sequence at the 5 end fused to the TRS and the
so-called body sequence. To visualize the FCoV strain Black
mRNAs, Northern blot analysis was performed, and the pre-
dicted six subgenomic mRNAs (sgmRNAs) were identified
(Fig. 1b). The exact leader-body junctions of FCoV Black
sgmRNAs were determined by leader-body-specific RT-PCRs
and sequencing analysis (Fig. 1c).
Cloning of a full-length cDNA of FCoV strain Black. For the
generation of an infectious clone of FCoV strain Black, we
used vaccinia virus as a cloning vector. It has previously been
shown that vaccinia viruses are suitable vectors for the cloning
of full-length cDNA of HCoV 229E, avian infectious bronchitis
virus, and mouse hepatitis virus (5, 8, 52).
The introduction of the full-length FCoV cDNA into vac-
cinia virus genome was carried out in two steps as illustrated in
Fig. 2. First, we constructed four plasmids, pA, pD, pE, and pF,
comprising segments which covered the major part of the ge-
TABLE 1. Predicted protease cleavage sites of FCoV strain Black
replicase polyproteins
Cleavage
product Polyprotein
Position in polyprotein
(amino acid residues) Size (aa)
a
nsp-1 pp1a/pp1ab 1Met-Gly110 110
nsp-2 pp1a/pp1ab 111Ala-Gly879 769
nsp-3 pp1a/pp1ab 880Gly-Gly2402 1523
nsp-4 pp1a/pp1ab 2403Ser-Gln2892 490
nsp-5 pp1a/pp1ab 2893Ser-Gln3194 302
nsp-6 pp1a/pp1ab 3195Ser-Gln3488 294
nsp-7 pp1a/pp1ab 3489Ser-Gln3571 83
nsp-8 pp1a/pp1ab 3572Ser-Gln3766 195
nsp-9 pp1a/pp1ab 3767Asn-Gln3877 111
nsp-10 pp1a/pp1ab 3878Ala-Gln4012 135
nsp-11 pp1a 4013Gly-Asp4032 19
nsp-12 pp1ab 4013Gly-Gln4942 929
nsp-13 pp1ab 4943Ala-Gln5541 599
nsp-14 pp1ab 5542Ala-Gln6060 519
nsp-15 pp1ab 6061Ser-Gln6399 339
nsp-16 pp1ab 6400Ser-Pro6699 300
a aa, amino acids.
FIG. 2. Schematic diagram for the introduction of the full-length FCoV strain Black cDNA into the vaccinia virus genome. In the first phase,
fragments A, D, E, and F (gray boxes) derived from plasmids pA, pD, pE, and pF were ligated into the vaccinia virus (VV) genome (white boxes).
In the second phase, to complete the full-length FCoV strain Black cDNA, fragments BC-1, -2, and -3 were introduced using two rounds of vaccinia
virus-mediated homologous recombination with gpt-positive and gpt-negative selection using the plasmids pGPT-BC1/3 and pBC-2.
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nome. DNA fragments A, D, E, and F prepared from plasmids
were used for in vitro ligation, and the resulting product was
ligated without further purification into NotI-cleaved vaccinia
virus DNA in the presence of NotI enzyme. Fowlpox virus-
infected CV-1 cells were transfected with this DNA to recover
recombinant vaccinia virus (vrecFCoV-ADEF) as described
previously (52). The identity of vrecFCoV-ADEF was verified
by sequencing the FCoV insert, and it was used as parental
virus for the introduction of the missing FCoV genome seg-
ment (nt 5083 to 15775) in a second step by two rounds of
vaccinia virus-mediated homologous recombination using the
Escherichia coli gpt gene as a positive or negative selection
marker, as described previously (8, 28). The vaccinia virus
vrecFCoV-BC-2 was generated from vrecFCoV-ADEF by
introducing the BC-1, gpt, and BC-3 fragments encoded by the
plasmid pGPT-BC-1/3. After three rounds of plaque purifica-
tion under gpt-positive selection, the recombinant vaccinia vi-
rus clone vrecFCoV-BC-2 was obtained, and the identity was
confirmed by sequence analysis. To obtain the full-length
FCoV cDNA-containing vaccinia virus vrecFCoV, the gpt gene
was replaced by fragment BC-2. This involved the recombina-
tion of vrecFCoV-BC-2 with plasmid pBC-2 and gpt-negative
selection. Finally, the sequence of the full-length FCoV insert
was verified by sequence analysis. The nucleotide differences
between vrecFCoV sequence and the initially determined
FCoV strain Black sequence are depicted in Table 2. In total,
we introduced 14 silent nucleotide changes, which served as
diagnostic markers to identify recombinant FCoV Black (see
below).
Generation of recombinant FCoV strain Black. To rescue
the recombinant FCoV strain Black, genomic DNA from pu-
rified vaccinia virus vrecFCoV was prepared, digested with
ClaI enzyme, and in vitro transcribed using bacteriophage T7
RNA polymerase. It has been previously shown for other CoVs
that rescue of recombinant CoVs from cloned cDNA is facil-
itated by N protein expression (5, 8, 59). Therefore, we gen-
erated a stable BHK cell line expressing the FCoV strain Black
N protein (BHK-FCoV-N). The in vitro transcribed recombi-
nant FCoV strain Black genomic RNA was electroporated into
BHK-FCoV-N cells, and the cells were subsequently coculti-
vated with FCWF cells. At 2 to 3 days posttransfection, the
supernatant was harvested and transferred to fresh FCWF
cells. After 2 to 3 days of incubation, cytopathic effect was
observed, and the supernatant containing recombinant FCoV
strain Black viruses was collected for further analysis. First, the
identity of recFCoV strain Black was confirmed by RT-PCR
sequencing analysis using poly(A)-containing RNA from
recFCoV strain Black-infected FCWF cells. DNA fragments
amplified by RT-PCR contained the diagnostic mutations
which allowed discrimination between parental and recombi-
nant FCoVs (Fig. 3a). This result demonstrated that we had
indeed rescued a recFCoV strain Black. Second, the pheno-
type of recFCoV was analyzed in tissue culture. The recombi-
nant virus has growth kinetics similar to the wild-type virus,
replicates to the same titer (Fig. 3b), and leads to the same
plaque morphology (data not shown).
Generation of recFCoV Black encoding reporter genes. Ef-
ficient expression of foreign genes by CoVs has been previously
described (9, 11, 16, 45, 47). In particular, the introduction of
TABLE 2. Silent nucleotide changes between vrecFCoV
and FCoV strain Black
Position in
the vrecFCoV
genome (nt)
Change of
nucleotide from
FCoV Black
485 .........................................................................................T3 C
2784 .......................................................................................C3 T
4285 .......................................................................................T3 C
7091 .......................................................................................C3 T
7326 .......................................................................................T3 C
8036 .......................................................................................A3 G
10973 .....................................................................................T3 C
13717 .....................................................................................A3 G
16498 .....................................................................................T3 A
17914 .....................................................................................T3 C
18673 .....................................................................................A3 G
21597 .....................................................................................T3 C
25776 .....................................................................................T3 C
26648 .....................................................................................T3 C
FIG. 3. Analysis of recFCoV. (a) Sequence analysis of the FCoV strain Black and recFCoV in a region containing a silent marker mutation
(at nt 485; indicated by an asterisk). (b) Growth kinetics of FCoV strain Black or recFCoV after infection of FCWF cells (MOI of 0.1). wt, wild
type; p.i., postinfection.
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reporter genes into CoV genomes or replicon RNAs has been
demonstrated to greatly facilitate the studies of CoV replica-
tion and transcription in target cells (28, 51). We replaced the
accessory 3abc genes by genes encoding the GFP and RL,
resulting in the recombinant viruses recFCoV-GFP and
recFCoV-RL, respectively (Fig. 4a). Both viruses replicated
efficiently in FCWF cells, displayed the same plaque morphol-
ogy, and reached nearly the same titers as the parental FCoV
strain Black (Fig. 4b). Furthermore, the heterologous genes
were stably retained for at least six passages in FCWF cells
(data not shown). To demonstrate reporter gene expression,
FCWF cells were infected with recFCoV-GFP and recFCoV-
RL. After recFCoV-GFP infection, green fluorescent cells
could easily be detected by fluorescence microscopy, confirm-
ing the expression of GFP (Fig. 4c). recFCoV-RL-infected
cells were harvested at different time points, and RL-activity
was detectable in cell lysates. The level of RL expression was
found to correlate with increasing viral titers during the course
of infection (Fig. 4d).
Infection of feline monocytes and DCs with recombinant
FCoV encoding reporter genes. FCoVs are known to cause in
their natural host subclinical, persistent infection as well as
lethal disease. It has been speculated that the ability of FCoV
to efficiently infect and replicate in monocytic cells determines
the severity of disease (13, 44, 50). Feline monocytes have been
shown previously to be susceptible to type II FCoV infection,
although the number of infected cells was usually very low (13).
In order to investigate whether type I FCoV strain Black can
infect and replicate in monocytes, we isolated feline CD14
monocytes from peripheral blood using anti-human CD14
magnetic beads (49). First, feline CD14 monocytes were in-
fected (MOI of 0.1) with the parental FCoV strain Black and
recFCoV-RL. Interestingly, we were not able to detect efficient
replication of FCoV strain Black in monocytes, and even in-
fection with the recFCoV-RL virus did not result in the detec-
tion of RL expression (data not shown). This may indicate that
feline monocytes are not susceptible to type I FCoV strain
Black infection. Alternatively, only a very limited, minor frac-
FIG. 4. Generation and analysis of recFCoV expressing reporter genes. (a) The structural relationship of the FCoV strain Black and the
recombinant viruses recFCoV-GFP and recFCoV-RL is shown. ORFs are indicated as boxes. The insertion site of the heterologous reporter gene
sequence is depicted together with TRS elements and start and stop codons. (b) Growth kinetics of recFCoV-GFP and recFCoV-RL compared
to the parental FCoV strain wt Black (wt) after infection of FCWF cells (MOI of 0.1). (c) Detection of GFP expression in recFCoV-GFP-infected
(MOI of 0.1) FCWF cells 24 h postinfection (magnification, 100; Leica DM IL fluorescence microscope). (d) Kinetics of RL expression in
recFCoV-RL-infected (MOI of 0.1) FCWF cells. p.i., postinfection; RLU, relative light units.
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tion of monocytes was infected, and RL expression or titers
were too low for detection. To clarify this point, we infected
feline CD14 monocytes with recFCoV-GFP and monitored
GFP expression by fluorescence microscopy. As shown in Fig.
5a, we were able to identify GFP-expressing monocytes; how-
ever, the number of green fluorescent cells was extremely low
(0.01%). This low number of infected cells would explain
why we could not demonstrate luciferase activity. To further
assess the ability of FCoV strain Black to infect and replicate
in monocyte-derived cells, we prepared feline macrophages
and DCs from the CD14 monocytes using hrGM-CSF or
hrGM-CSF together with human recombinant IL-4, respec-
tively (49). After CD14 monocytes were cultured in the pres-
ence of hrGM-CSF for 6 days, about 30% of the cells displayed
typical macrophage morphology. Again, infection with FCoV
Black or recFCoV-RL did not result in the detection of effi-
cient replication. However, after recFCoV-GFP infection, we
were able to detect cells displaying green fluorescence but only
a very low number; however, those cells did not show the
typical macrophage morphology. Finally, infection of DCs was
analyzed, and, similar to the results described above, no effi-
cient replication was observed. We were, however, able to
detect green fluorescent cells that displayed the characteristic
DC morphology (Fig. 5b). Taken together, the susceptibility of
CD14 monocytes, macrophages, and DCs to type I FCoV
infection appears to be limited, and only the use of a recom-
binant GFP-expressing FCoV enabled us to demonstrate type
I FCoV replication in a small subset of these cells.
DISCUSSION
Type I FCoV causes approximately 80% of the natural in-
fections of cats, while the other 20% are due to type II FCoV.
Until now most studies on FCoVs focused on type II viruses,
mainly because, in contrast to type I FCoV, they can be easily
propagated in cell culture. Here, we have analyzed the genome
organization and replication of a type I FCoV, the Black strain.
We have cloned the full-length FCoV strain Black cDNA into
a vaccinia virus cloning vector which allowed us to generate
recombinant type I FCoV. Finally, we have addressed to what
extent monocytic cells are susceptible to type I FCoV infection.
Our sequence analysis revealed the characteristic CoV ge-
nome organization. The replicase gene comprises two large
ORFs; within the polyprotein pp1a/1ab, 14 protease cleavage
sites were predicted with 16 nsps as end products. The analysis
of the structural gene region revealed that type I FCoV strain
Black encodes four structural proteins in the order S-E-M-N.
Between the S and E genes and downstream of the N gene, we
have identified the accessory 3abc and 7ab genes, respectively.
A 62-nt deletion in the ORF 3bc region results in the fusion of
ORFs 3bc, and a nonsense mutation at nt 28441 leads to
premature termination of the ORF7b gene product. FCoV
strain Black expresses a characteristic set of six nested sgmRNAs.
The determination of the leader-body junctions allowed us to
identify the core TRS of strain Black. In contrast to published
type II FCoV genome sequences (14), we did not find any
evidence for a recombination event between FCoV and CCoV
(or any other CoV).
We have chosen the FCoV strain Black for several reasons.
First, it is a type I FCoV, the most prevalent type of natural
FCoV infections. Second, this isolate can be propagated in cell
culture with peak titers of up to 105 times the 50% tissue
culture infective dose in FCWF cells. Third, we have chosen
the high-passage (HP) FCoV strain Black stock to generate
our reverse genetic system in order to facilitate the recovery of
recombinant viruses. We have obtained low-passage (LP) and
high-passage (HP) stocks of the original FCoV strain Black.
According to the available literature, the LP virus is virulent
and causes FIP in experimentally infected cats, while the HP
virus is attenuated and no longer able to induce FIP (42).
Because it is not documented whether our HP Black strain
represents the HP stock that was used in previous in vivo
experiments, its pathogenicity remains to be determined. Our
preliminary sequencing analyses of the LP virus stock revealed
a number of nucleotide differences, mainly within the acces-
sory gene regions (unpublished data). Moreover, we observed
that the LP virus stock contains a mixture of viruses including
the HP virus that we have cloned in vaccinia virus. The reverse
genetic system for the type I FCoV strain Black will now allow
the reconstitution of LP virus(es) and its phenotypic analysis in
vitro and in vivo. Since our reverse genetic system for type I
FCoV is based on cloned full-length cDNA, the entire genome
is now amenable to mutagenesis. Thus far, the genome of an
FCoV could be modified only within the 3 third of the genome
(21). However, there is now accumulating evidence for a role
of replicase gene product(s) in the pathogenesis of CoVs (48,
60). Accordingly, the reconstitution of LP virus(es) may in-
clude replicase gene product(s) (i.e., regions of the 5 two-
thirds of the genome).
The reverse genetic system also allows the identification of
type I FCoV target cells. Along this line we have generated
recFCoV encoding GFP or RL reporter proteins (recFCoV-
GFP and recFCoV-RL). The GFP and RL genes were stably
retained in the rescued viruses, and their efficient growth in
feline cells confirmed the general observation that accessory
genes are dispensable for CoV replication in vitro (6, 10, 21,
22, 40, 46, 58). We have chosen to evaluate the infection of
feline CD14 monocytes, macrophages, and DCs with FCoV
strain Black, since these cell types most likely represent im-
portant target cells for FCoV and other CoVs in vivo (3, 7, 35,
37, 41, 56). For FCoV infection, monocytes are considered to
contribute to the dissemination of the virus throughout the
host organism. Our analyses revealed that efficient replication
of type I FCoV can be observed in only very few monocytes,
macrophages, and DCs. Notably, the detection of type I FCoV-
FIG. 5. recFCoV-GFP infection of feline monocytic cells. Shown
are images of recFCoV-GFP-infected (MOI of 0.1) feline CD14
monocytes (a) and feline DCs (b) at 24 h postinfection (Leica DM IL
fluorescence microscope; magnification, 100).
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infected cells was possible only through the expression of GFP
by a recombinant virus produced with our reverse genetic sys-
tem. It has previously been reported that less than 1% of the
monocytes could be infected in vitro with the most commonly
investigated type II FCoV, strain 79-1146 (13). Since type II
79-1146 grows in FCWF cells to 100-fold higher titers than the
type I FCoV strain Black (data not shown), a direct compari-
son of both types is required to assess if there are differences
in the susceptibility of monocytes between type II and type I
FCoV infections. Further studies are also required to evaluate
if there are differences between type II and type I FCoV
replication in feline macrophages and DCs. Notably, the use of
commercially available human cytokines (hrGM-CSF and hu-
man recombinant IL-4) enabled us to generate feline DCs
from CD14 monocytes. To our knowledge, the detection of
recFCoV-GFP-mediated GFP expression in feline DCs repre-
sents the first demonstration that FCoV is able to infect and
replicate in DCs. DCs have been shown to represent important
target cells for a number of CoVs. In the murine system it has
been shown that murine hepatitis virus can infect DCs and that
plasmacytoid DCs are important for the induction of type I
interferon responses (7). Furthermore, besides their function
in innate immune responses, DCs are known to be key medi-
ators in shaping the emerging adaptive immune response.
Thus, the study of FCoV target cells represents an important
aspect of FCoV research and may help provide more insight
into the pathogenesis of FCoV-induced disease.
The limited susceptibility of monocytes, DCs, and macro-
phages to type I FCoV infection observed in this study raises
the question of which receptor(s) is involved in FCoV infec-
tion. It has been previously reported that type II FCoVs use
fAPN (feline CD13) as a receptor (53). Nevertheless, it should
be noted that type II FCoV strains can also display differences
in the ability to replicate in macrophages (13, 44, 50), and it has
been proposed that the type II FCoV spike protein is the major
determinant of macrophage tropism. Detailed analyses re-
vealed that the type II FCoV spike-binding domain resides
within fAPN residues 670 to 840, a region that is also impor-
tant for entry of porcine transmissible gastroenteritis virus and
CCoV into permissive cells (23, 57). Interestingly, the type II
FCoV sequence indicates that recombination between type I
FCoV and CCoV led to the replacement of the type I FCoV S
gene by the CCoV S gene. Thus, it appears questionable
whether type I FCoVs also use fAPN as a receptor (15, 32).
Further studies are required to resolve which cellular receptor
is used for type I FCoV entry and whether a pronounced
macrophage tropism correlates with more virulent type I
FCoV phenotypes in vivo. Clearly, the reverse genetic system
for type I FCoV will greatly facilitate addressing these ques-
tions.
In summary, we have analyzed the genome organization and
replication of a type I FCoV and established a reverse genetic
system for this FCoV serotype. The system is based on cloned,
full-length cDNA and enables the manipulation of the entire
genome. The reverse genetic analysis of type I FCoV will lead
to new insights into important aspects of FCoV target cell
tropism, receptor usage, and pathogenicity. Finally, this system
will enable the construction of recombinant FCoV vaccines
designed to protect against homologous and heterologous vi-
rus-induced diseases of cats.
ACKNOWLEDGMENTS
We thank B. Ludewig, R. Maier, K. K. Eriksson, L. Cervantes-
Barraga´n, R. Zu¨st, D. Makia, B. Weibel, M. Meli, and B. Riond for
technical help and helpful discussions. Furthermore, we thank G. L.
Smith, N. Tautz, P. Britton, and R. de Groot for providing valuable
materials and M. Ko¨nig and B. Bank-Wolf for diagnostic tests.
R.H.-L. is the recipient of a professorship by the Swiss National
Science Foundation (PP00B 102866). This work was supported by the
Swiss National Science Foundation.
REFERENCES
1. Addie, D. D., and O. Jarrett. 2001. Use of a reverse-transcriptase polymerase
chain reaction for monitoring the shedding of feline coronavirus by healthy
cats. Vet. Rec. 148:649–653.
2. Addie, D. D., I. A. Schaap, L. Nicolson, and O. Jarrett. 2003. Persistence and
transmission of natural type I feline coronavirus infection. J. Gen. Virol.
84:2735–2744.
3. Berg, A. L., K. Ekman, S. Belak, and M. Berg. 2005. Cellular composition
and interferon-gamma expression of the local inflammatory response in
feline infectious peritonitis (FIP). Vet. Microbiol. 111:15–23.
4. Black, J. W. 1980. Recovery and in vitro cultivation of a coronavirus from
laboratory-induced cases of feline infectious peritonitis (FIP). Vet. Med.
Small Anim. Clin. 75:811–814.
5. Casais, R., V. Thiel, S. G. Siddell, D. Cavanagh, and P. Britton. 2001.
Reverse genetics system for the avian coronavirus infectious bronchitis virus.
J. Virol. 75:12359–12369.
6. Casais, R., M. Davies, D. Cavanagh, and P. Britton. 2005. Gene 5 of the
avian coronavirus infectious bronchitis virus is not essential for replication.
J. Virol. 79:8065–8078.
7. Cervantes-Barragan, L., R. Zust, F. Weber, M. Spiegel, K. S. Lang, S. Akira,
V. Thiel, and B. Ludewig. 2007. Control of coronavirus infection through
plasmacytoid dendritic-cell-derived type I interferon. Blood 109:1131–1137.
8. Coley, S. E., E. Lavi, S. G. Sawicki, L. Fu, B. Schelle, N. Karl, S. G. Siddell,
and V. Thiel. 2005. Recombinant mouse hepatitis virus strain A59 from
cloned, full-length cDNA replicates to high titers in vitro and is fully patho-
genic in vivo. J. Virol. 79:3097–3106.
9. Curtis, K. M., B. Yount, and R. S. Baric. 2002. Heterologous gene expression
from transmissible gastroenteritis virus replicon particles. J. Virol. 76:1422–
1434.
10. de Haan, C. A., P. S. Masters, X. Shen, S. Weiss, and P. J. Rottier. 2002. The
group-specific murine coronavirus genes are not essential, but their deletion,
by reverse genetics, is attenuating in the natural host. Virology 296:177–189.
11. de Haan, C. A., L. van Genne, J. N. Stoop, H. Volders, and P. J. Rottier. 2003.
Coronaviruses as vectors: position dependence of foreign gene expression.
J. Virol. 77:11312–11323.
12. de Haan, C. A., B. J. Haijema, D. Boss, F. W. Heuts, and P. J. Rottier. 2005.
Coronaviruses as vectors: stability of foreign gene expression. J. Virol. 79:
12742–12751.
13. Dewerchin, H. L., E. Cornelissen, and H. J. Nauwynck. 2005. Replication of
feline coronaviruses in peripheral blood monocytes. Arch. Virol. 150:2483–
2500.
14. Dye, C., and S. G. Siddell. 2005. Genomic RNA sequence of Feline coro-
navirus strain FIPV WSU-79/1146. J. Gen. Virol. 86:2249–2253.
15. Dye, C., N. Temperton, and S. G. Siddell. 2007. Type I feline coronavirus
spike glycoprotein fails to recognize aminopeptidase N as a functional re-
ceptor on feline cell lines. J. Gen. Virol. 88:1753–1760.
16. Fischer, F., C. F. Stegen, C. A. Koetzner, and P. S. Masters. 1998. Construc-
tion of a mouse hepatitis virus recombinant expressing a foreign gene. Adv.
Exp. Med. Biol. 440:291–295.
17. Foley, J. E., A. Poland, J. Carlson, and N. C. Pedersen. 1997. Patterns of
feline coronavirus infection and fecal shedding from cats in multiple-cat
environments. J. Am. Vet. Med. Assoc. 210:1307–1312.
18. Gonzalez, J. M., P. Gomez-Puertas, D. Cavanagh, A. E. Gorbalenya, and L.
Enjuanes. 2003. A comparative sequence analysis to revise the current
taxonomy of the family Coronaviridae. Arch. Virol. 148:2207–2235.
19. Gorbalenya, A. E., L. Enjuanes, J. Ziebuhr, and E. J. Snijder. 2006. Nidovi-
rales: evolving the largest RNA virus genome. Virus Res. 117:17–37.
20. Gunn-Moore, D. A., T. J. Gruffydd-Jones, and D. A. Harbour. 1998. Detec-
tion of feline coronaviruses by culture and reverse transcriptase-polymerase
chain reaction of blood samples from healthy cats and cats with clinical feline
infectious peritonitis. Vet. Microbiol. 62:193–205.
21. Haijema, B. J., H. Volders, and P. J. Rottier. 2003. Switching species tropism:
an effective way to manipulate the feline coronavirus genome. J. Virol.
77:4528–4538.
22. Haijema, B. J., H. Volders, and P. J. Rottier. 2004. Live, attenuated coro-
navirus vaccines through the directed deletion of group-specific genes pro-
vide protection against feline infectious peritonitis. J. Virol. 78:3863–3871.
23. Hegyi, A., and A. F. Kolb. 1998. Characterization of determinants involved in
the feline infectious peritonitis virus receptor function of feline aminopep-
tidase N. J. Gen. Virol. 79:1387–1391.
1858 TEKES ET AL. J. VIROL.
24. Herrewegh, A. A., R. J. de Groot, A. Cepica, H. F. Egberink, M. C. Horzinek,
and P. J. Rottier. 1995. Detection of feline coronavirus RNA in feces, tissues,
and body fluids of naturally infected cats by reverse transcriptase PCR.
J. Clin. Microbiol. 33:684–689.
25. Herrewegh, A. A., H. Vennema, M. C. Horzinek, P. J. Rottier, and R. J. de
Groot. 1995. The molecular genetics of feline coronaviruses: comparative
sequence analysis of the ORF7a/7b transcription unit of different biotypes.
Virology 212:622–631.
26. Herrewegh, A. A.,M.Mahler,H. J.Hedrich, B. L.Haagmans,H. F. Egberink,M.C.
Horzinek, P. J. Rottier, and R. J. de Groot. 1997. Persistence and evolution of feline
coronavirus in a closed cat-breeding colony. Virology 234:349–363.
27. Herrewegh, A. A., I. Smeenk, M. C. Horzinek, P. J. Rottier, and R. J. de
Groot. 1998. Feline coronavirus type II strains 79–1683 and 79–1146 origi-
nate from a double recombination between feline coronavirus type I and
canine coronavirus. J. Virol. 72:4508–4514.
28. Hertzig, T., E. Scandella, B. Schelle, J. Ziebuhr, S. G. Siddell, B. Ludewig,
and V. Thiel. 2004. Rapid identification of coronavirus replicase inhibitors
using a selectable replicon RNA. J. Gen. Virol. 85:1717–1725.
29. Hohdatsu, T., S. Okada, and H. Koyama. 1991. Characterization of mono-
clonal antibodies against feline infectious peritonitis virus type II and anti-
genic relationship between feline, porcine, and canine coronaviruses. Arch.
Virol. 117:85–95.
30. Hohdatsu, T., T. Sasamoto, S. Okada, and H. Koyama. 1991. Antigenic
analysis of feline coronaviruses with monoclonal antibodies (MAbs): prep-
aration of MAbs which discriminate between FIPV strain 79–1146 and
FECV strain 79–1683. Vet. Microbiol. 28:13–24.
31. Hohdatsu, T., S. Okada, Y. Ishizuka, H. Yamada, and H. Koyama. 1992. The
prevalence of types I and II feline coronavirus infections in cats. J. Vet. Med.
Sci. 54:557–562.
32. Hohdatsu, T., Y. Izumiya, Y. Yokoyama, K. Kida, and H. Koyama. 1998.
Differences in virus receptor for type I and type II feline infectious peritonitis
virus. Arch. Virol. 143:839–850.
33. Kennedy, M., N. Boedeker, P. Gibbs, and S. Kania. 2001. Deletions in the 7a
ORF of feline coronavirus associated with an epidemic of feline infectious
peritonitis. Vet. Microbiol. 81:227–234.
34. Kennedy, M., S. Citino, A. H. McNabb, A. S. Moffatt, K. Gertz, and S. Kania.
2002. Detection of feline coronavirus in captive Felidae in the USA. J. Vet.
Diagn. Investig. 14:520–522.
35. Kipar, A., S. Bellmann, J. Kremendahl, K. Kohler, and M. Reinacher. 1998.
Cellular composition, coronavirus antigen expression and production of spe-
cific antibodies in lesions in feline infectious peritonitis. Vet. Immunol.
Immunopathol. 65:243–257.
36. Kipar, A., S. Bellmann, D. A. Gunn-Moore, W. Leukert, K. Kohler, S.
Menger, and M. Reinacher. 1999. Histopathological alterations of lymphatic
tissues in cats without feline infectious peritonitis after long-term exposure
to FIP virus. Vet. Microbiol. 69:131–137.
37. Kipar, A., H. May, S. Menger, M. Weber, W. Leukert, and M. Reinacher.
2005. Morphologic features and development of granulomatous vasculitis in
feline infectious peritonitis. Vet. Pathol. 42:321–330.
38. Kummrow, M., M. L. Meli, M. Haessig, E. Goenczi, A. Poland, N. C. Pedersen, R.
Hofmann-Lehmann, and H. Lutz. 2005. Feline coronavirus serotypes 1 and 2:
seroprevalence and association with disease in Switzerland. Clin. Diagn. Lab. Im-
munol. 12:1209–1215.
39. Meli, M., A. Kipar, C. Muller, K. Jenal, E. Gonczi, N. Borel, D. Gunn-Moore,
S. Chalmers, F. Lin, M. Reinacher, and H. Lutz. 2004. High viral loads
despite absence of clinical and pathological findings in cats experimentally
infected with feline coronavirus (FCoV) type I and in naturally FCoV-
infected cats. J. Feline Med. Surg. 6:69–81.
40. Ortego, J., I. Sola, F. Almazan, J. E. Ceriani, C. Riquelme, M. Balasch, J.
Plana, and L. Enjuanes. 2003. Transmissible gastroenteritis coronavirus
gene 7 is not essential but influences in vivo virus replication and virulence.
Virology 308:13–22.
41. Paltrinieri, S., V. Grieco, S. Comazzi, and M. Cammarata Parodi. 2001.
Laboratory profiles in cats with different pathological and immunohisto-
chemical findings due to feline infectious peritonitis (FIP). J. Feline Med.
Surg. 3:149–159.
42. Pedersen, N. C., and J. W. Black. 1983. Attempted immunization of cats
against feline infectious peritonitis, using avirulent live virus or sublethal
amounts of virulent virus. Am. J. Vet. Res. 44:229–234.
43. Pedersen, N. C., J. W. Black, J. F. Boyle, J. F. Evermann, A. J. McKeirnan,
and R. L. Ott. 1984. Pathogenic differences between various feline corona-
virus isolates, p. 356–380. In P. J. Rottier, B. A. M. Zeijst, W. J. M. Spaan,
and M. C. Horzinek (ed.), Molecular biology and pathogenesis of coronavi-
ruses. Plenum, New York, NY.
44. Rottier, P. J., K. Nakamura, P. Schellen, H. Volders, and B. J. Haijema.
2005. Acquisition of macrophage tropism during the pathogenesis of feline
infectious peritonitis is determined by mutations in the feline coronavirus
spike protein. J. Virol. 79:14122–14130.
45. Sarma, J. D., E. Scheen, S. H. Seo, M. Koval, and S. R. Weiss. 2002.
Enhanced green fluorescent protein expression may be used to monitor
murine coronavirus spread in vitro and in the mouse central nervous system.
J. Neurovirol. 8:381–391.
46. Schwarz, B., E. Routledge, and S. G. Siddell. 1990. Murine coronavirus
nonstructural protein ns2 is not essential for virus replication in transformed
cells. J. Virol. 64:4784–4791.
47. Sola, I., S. Alonso, S. Zuniga, M. Balasch, J. Plana-Duran, and L. Enjuanes.
2003. Engineering the transmissible gastroenteritis virus genome as an ex-
pression vector inducing lactogenic immunity. J. Virol. 77:4357–4369.
48. Sperry, S. M., L. Kazi, R. L. Graham, R. S. Baric, S. R. Weiss, and M. R.
Denison. 2005. Single-amino-acid substitutions in open reading frame
(ORF) 1b-nsp14 and ORF 2a proteins of the coronavirus mouse hepatitis
virus are attenuating in mice. J. Virol. 79:3391–3400.
49. Sprague, W. S., M. Pope, and E. A. Hoover. 2005. Culture and comparison of
feline myeloid dendritic cells vs macrophages. J. Comp. Pathol. 133:136–145.
50. Stoddart, C. A., and F. W. Scott. 1988. Isolation and identification of feline
peritoneal macrophages for in vitro studies of coronavirus-macrophage in-
teractions. J. Leukoc. Biol. 44:319–328.
51. Thiel, V., J. Herold, B. Schelle, and S. G. Siddell. 2001. Viral replicase gene
products suffice for coronavirus discontinuous transcription. J. Virol. 75:
6676–6681.
52. Thiel, V., J. Herold, B. Schelle, and S. G. Siddell. 2001. Infectious RNA
transcribed in vitro from a cDNA copy of the human coronavirus genome
cloned in vaccinia virus. J. Gen. Virol. 82:1273–1281.
53. Tresnan, D. B., R. Levis, and K. V. Holmes. 1996. Feline aminopeptidase N
serves as a receptor for feline, canine, porcine, and human coronaviruses in
serogroup I. J. Virol. 70:8669–8674.
54. Vennema, H., A. Poland, J. Foley, and N. C. Pedersen. 1998. Feline infectious
peritonitis viruses arise by mutation from endemic feline enteric coronavi-
ruses. Virology 243:150–157.
55. Vennema, H. 1999. Genetic drift and genetic shift during feline coronavirus
evolution. Vet. Microbiol. 69:139–141.
56. Ward, J. M. 1970. Morphogenesis of a virus in cats with experimental feline
infectious peritonitis. Virology 41:191–194.
57. Wentworth, D. E., and K. V. Holmes. 2001. Molecular determinants of
species specificity in the coronavirus receptor aminopeptidase N (CD13):
influence of N-linked glycosylation. J. Virol. 75:9741–9752.
58. Youn, S., J. L. Leibowitz, and E. W. Collisson. 2005. In vitro assembled,
recombinant infectious bronchitis viruses demonstrate that the 5a open read-
ing frame is not essential for replication. Virology 332:206–215.
59. Yount, B., M. R. Denison, S. R. Weiss, and R. S. Baric. 2002. Systematic
assembly of a full-length infectious cDNA of mouse hepatitis virus strain
A59. J. Virol. 76:11065–11078.
60. Zust, R., L. Cervantes-Barragan, T. Kuri, G. Blakqori, F. Weber, B.
Ludewig, and V. Thiel. 2007. Coronavirus non-structural protein 1 is a major
pathogenicity factor: implications for the rational design of coronavirus vac-
cines. PLoS Pathog. 3:e109.
VOL. 82, 2008 TYPE I FELINE CORONAVIRUS REVERSE GENETIC ANALYSIS 1859
